- FORTE trial: upfront carfilzomib (K) + lenalidomide (R) + dexamethasone (d) (KRd) with or without autologous stem cell transplantation (ASCT). This regimen led to superior outcomes and higher minimal residual disease (MRD) negativity versus competitor in the prospective randomized phase III FORTE trial. These results indicated that KRd is an viable induction regimen, prior to ASCT, but also can be used for consolidation and maintenance after ASCT.
- The combination of bortezomib + daratumumab led to superior outcomes with high quality responses. This is the first time a monoclonal antibody has been used in the first-line treatment of patients with NDMM, demonstrating a high benefit and prolonged progression-free survival (PFS).